{"entity":{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Nimbus Saturn, Inc., active and no longer recruiting.","summary":"A Study of NDI 1150-101 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05128487 by Nimbus Saturn, Inc., with 106 participants planned, started 2021-11-05 and due to reach its primary completion in 2025-02. Interventions recorded: NDI-101150, Pembrolizumab. Conditions listed: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05128487","url":"https://clinicaltrials.gov/study/NCT05128487"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05128487","phase":"1/2","setting":"A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors","sponsor":"Nimbus Saturn, Inc.","enrolled":106,"outcomes":[]},"route":"/trials/nct05128487/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}